TrialEuropean journal of haematology2021

One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab.

Austin G Kulasekararaj et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.